Atlanta, GA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (“Streamline” or the “Company”) (Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, today announced financial results for the third quarter of fiscal 2022, which ended October 31, 2022.
Fiscal Third Quarter and Nine Months Ended October 31, 2022 GAAP Financial Results
The following financial results have been prepared in accordance with Generally Accepted Accounting Principles (“GAAP”). Fiscal third quarter 2022 financial results represent the consolidation of the Company with Avelead Consulting, LLC (“Avelead”), which was acquired in the fiscal third quarter 2021. Fiscal third quarter 2021 GAAP financial results reflect results from Avelead’s operations from the date of acquisition, August 16, 2021.
Total revenue for the third quarter of fiscal 2022 was $6.2 million, a 13% increase from $5.5 million during the third quarter of fiscal 2021. The increase in revenue for the quarter was the result of higher revenue from SaaS and professional services. Total revenue for the nine months ended October 31, 2022 increased 60% to $18.1 million compared to $11.3 million for the nine months ended October 31, 2021. During the third quarter of fiscal 2022, SaaS revenue grew $0.4 million or 14% compared to the third quarter of fiscal 2021 and during the nine months ended October 31, 2022, $3.8 million or 72% compared to the first nine months of fiscal 2021.
Loss from continuing operations for the third quarter of fiscal 2022 was ($3.1) million, as compared to loss from continuing operations of ($4.4) million during the third quarter of fiscal 2021. Loss from continuing operations in the third quarter of fiscal 2021 included other expenses of ($0.6) million primarily related to interest expense and valuation adjustments.
Loss from continuing operations for the first nine months of fiscal 2022 was ($9.2) million, as compared to loss from continuing operations of ($6.9) million during the first nine months of fiscal 2021. During the first nine months of fiscal 2021 the Company reported a one time gain of $2.3 million of other income related to the forgiveness of the PPP loan, which was the primary driver of the higher loss from continuing operations for the first nine months of fiscal 2022.
Fiscal Third Quarter and Nine Months Ended October 31, 2022 Pro Forma and Non-GAAP Financial Results
The following financial results for Fiscal 2021 are pro forma and have not been prepared in accordance with GAAP. These pro forma financial results represent the consolidation of the Company with Avelead as if Avelead’s operations were fully recognized during the comparable period.
Total revenue for the third quarter of fiscal 2022 was $6.2 million, up slightly compared to pro forma revenue of approximately $6.1 million for the third quarter of fiscal 2021. Total revenue for the nine months ended October 31, 2022 was $18.1 million, an increase of 9% compared to pro forma revenue of $16.6 million for the nine months ended October 31, 2021. For the third quarter of fiscal 2022, SaaS revenue comprised $3.2 million of revenue, up slightly compared to pro forma SaaS revenue of approximately $3.1 million for the third quarter of fiscal 2021. For the first nine months of fiscal 2022, SaaS revenue totaled $9.2 million, an increase of 7% compared to pro forma SaaS revenue of $8.6 million for the first nine months of fiscal 2021.
Total revenue of $6.2 million for the three months ended October 31, 2022 includes $2.8 million of revenue from Avelead. The pro forma revenue of approximately $6.1 million for the third quarter of fiscal 2021 includes $2.6 million of revenue from Avelead. Total revenue of $18.1 million for the nine months ended October 31, 2022 includes $7.8 million of revenue from Avelead. The pro forma revenue of approximately $16.6 million for the nine months ended October 31, 2021 includes $7.3 million of revenue from Avelead.
Adjusted EBITDA for the third quarter of fiscal 2022 was a loss of ($1.2) million, compared to an adjusted EBITDA loss of ($0.3) million in the third quarter of fiscal 2021. Adjusted EBITDA for the nine months ended October 31, 2022 was a loss of ($3.6) million, compared to an Adjusted EBITDA loss of ($1.7) million for the nine months ended October 31, 2021. The increased loss from Adjusted EBITDA during the third quarter and first nine months of fiscal 2022 was driven by increased headcount, higher spend on research and development, accrual for performance bonuses and increased travel and entertainment spend as compared to the prior year.
As of October 31, 2022, the Company’s total Booked SaaS Annual Contract Value (“ACV”) was $14.9 million. This can be compared to Booked SaaS ACV of $10.6 million as of January 31, 2022. Subsequent to the end of the third quarter of fiscal 2022, the Company successfully executed on new bookings, and as of November 30, 2022 the Company reported $15.9 million of Booked SaaS ACV. The Booked SaaS ACV represents the annualized value of all executed SaaS contracts, including contracts that have not been fully implemented, as of the measurement date, assuming any contract that expires during the twelve months following the measurement date is renewed on its existing terms unless the Company has knowledge of the non-renewal.
Management Commentary
“At the end of our third quarter, we initiated our strategic alignment entering a new chapter of the Streamline story enabling us to maintain growth while prioritizing near term cash generation,” said Tee Green, Chief Executive Officer, Streamline Health. “Our mission to ensure heathcare providers can capture 100% of the revenue they’ve earned is resonating in the market, and we maintain our expectation of exiting fiscal 2022 with at least $17 million of Booked SaaS ACV.”
Conference Call
The Company will conduct a conference call on Thursday, December 15, 2022 at 9:00 AM ET to review results and provide a corporate update. Interested parties can access the call by joining the live webcast: click here to register. You can also join by phone by dialing 877-407-8291.
A replay of the conference call will be available from Thursday, December 15, 2022, at 12:00 PM ET to Thursday, December 22, 2022 at 12:00 PM ET by dialing 877-660-6853 or 201-612-7415 with conference ID 1374705. An online replay of the presentation will also be available for six months following the presentation in the Investor Relations section of the Streamline website, www.streamlinehealth.net.
About Streamline Health
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net.
Non-GAAP Financial Measures
Streamline reports its financial results in accordance with U.S. generally accepted accounting principles (“GAAP”). Streamline’s management also evaluates and makes operating decisions using various other measures. One such measure is adjusted EBITDA, which is a non-GAAP financial measure. Streamline’s management believes that this measure provides useful supplemental information regarding the performance of Streamline’s business operations.
Streamline defines “adjusted EBITDA” as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, share-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, and professional and advisory fees. A table reconciling this measure to “loss from continuing operations” is included in this press release.
Booked SaaS ACV represents the annualized value of all executed SaaS contracts, including contracts that have not been fully implemented, as of the measurement date, assuming any contract that expires during the twelve months following the measurement date is renewed on its existing terms unless the Company has knowledge of the non-renewal. Booked SaaS ACV should be viewed independently of revenue and does not represent revenue calculated in accordance with GAAP on an annualized basis, as it is an operating metric that can be impacted by contract execution start and end dates and renewal rates. Booked SaaS ACV is not intended to be a replacement for, or forecast of, revenue. There is no GAAP measure comparable to Booked SaaS ACV.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Statements made by Streamline Health Solutions, Inc. that are not historical facts are forward-looking statements that are subject to certain risks, uncertainties and important factors that could cause actual results to differ materially from those reflected in the forward-looking statements included herein. Forward-looking statements contained in this press release include, without limitation, statements regarding the Company’s growth prospects, estimates of anticipated cash flow generation, anticipated bookings, recognition of revenue from contracts included in Booked SaaS ACV, industry trends and market growth, results of investments in sales and marketing, success of future products and related expectations and assumptions. These risks and uncertainties include, but are not limited to, the timing of contract negotiations and execution of contracts and the related timing of the revenue recognition related thereto, the potential cancellation of existing contracts or clients not completing projects included in the backlog and Booked SaaS ACV, the impact of competitive solutions and pricing, solution demand and market acceptance, new solution development and enhancement of current solutions, key strategic alliances with vendors and channel partners that resell the Company’s solutions, the ability of the Company to control costs, the effects of cost-containment measures implemented by the Company, availability of solutions from third party vendors, the healthcare regulatory environment, potential changes in legislation, regulation and government funding affecting the healthcare industry, healthcare information systems budgets, availability of healthcare information systems trained personnel for implementation of new systems, as well as maintenance of legacy systems, fluctuations in operating results, effects of critical accounting policies and judgments, changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or other similar entities, changes in economic, business and market conditions impacting the healthcare industry generally and the markets in which the Company operates and nationally, the Company’s ability to maintain compliance with the terms of its credit facilities, and other risks detailed from time to time in the Streamline Health Solutions, Inc. filings with the U. S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date hereof. The Company undertakes no obligation to publicly release the results of any revision to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.
Company Contact
Jacob Goldberger
Director, Investor Relations and FP&A
303-887-9625
This email address is being protected from spambots. You need JavaScript enabled to view it.
STREAMLINE HEALTH SOLUTIONS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(rounded to the nearest thousand dollars, except share and per share information)
| Three Months Ended October 31, | Nine Months Ended October 31, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Total Revenue | $ | 6,217,000 | $ | 5,514,000 | $ | 18,144,000 | $ | 11,333,000 | ||||||||
| Operating expenses: | ||||||||||||||||
| Cost of revenue | 3,570,000 | 2,623,000 | 9,983,000 | 5,496,000 | ||||||||||||
| Selling, general and administrative expense | 4,053,000 | 3,439,000 | 12,488,000 | 8,507,000 | ||||||||||||
| Research and development | 1,754,000 | 1,339,000 | 4,527,000 | 3,280,000 | ||||||||||||
| Acquisition-related costs | 2,000 | 1,933,000 | 141,000 | 2,710,000 | ||||||||||||
| Total operating expenses | 9,379,000 | 9,334,000 | 27,139,000 | 19,993,000 | ||||||||||||
| Operating loss | (3,162,000 | ) | (3,820,000 | ) | (8,995,000 | ) | (8,660,000 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest expense | (198,000 | ) | (85,000 | ) | (519,000 | ) | (107,000 | ) | ||||||||
| Loss on Extinguishment of Debt | — | (43,000 | ) | — | (43,000 | ) | ||||||||||
| Acquisition earnout valuation adjustments | 163,000 | (417,000 | ) | 188,000 | (417,000 | ) | ||||||||||
| Other | 68,000 | (10,000 | ) | 151,000 | (4,000 | ) | ||||||||||
| Forgiveness of PPP loan and accrued interest | — | — | — | 2,327,000 | ||||||||||||
| Loss from continuing operations before income taxes | (3,129,000 | ) | (4,375,000 | ) | (9,175,000 | ) | (6,904,000 | ) | ||||||||
| Income tax expense | (9,000 | ) | (4,000 | ) | (22,000 | ) | (9,000 | ) | ||||||||
| Loss from continuing operations | (3,138,000 | ) | (4,379,000 | ) | (9,197,000 | ) | (6,913,000 | ) | ||||||||
| Income from discontinued operations: | ||||||||||||||||
| Income from discontinued operations, net of tax | — | 69,000 | — | 401,000 | ||||||||||||
| Net loss | $ | (3,138,000 | ) | $ | (4,310,000 | ) | $ | (9,197,000 | ) | $ | (6,512,000 | ) | ||||
| Basic Earnings Per Share: | ||||||||||||||||
| Continuing operations | $ | (0.07 | ) | $ | (0.10 | ) | $ | (0.19 | ) | $ | (0.17 | ) | ||||
| Discontinued operations | — | 0.00 | — | 0.01 | ||||||||||||
| Net loss | $ | (0.07 | ) | $ | (0.10 | ) | $ | (0.19 | ) | $ | (0.16 | ) | ||||
| Weighted average number of common shares – basic | 47,730,009 | 45,709,952 | 47,329,923 | 41,498,873 | ||||||||||||
| Diluted Earnings Per Share: | ||||||||||||||||
| Continuing operations | $ | (0.07 | ) | $ | (0.10 | ) | $ | (0.19 | ) | $ | (0.17 | ) | ||||
| Discontinued operations | — | 0.00 | — | $ | 0.01 | |||||||||||
| Net loss | $ | (0.07 | ) | $ | (0.10 | ) | $ | (0.19 | ) | $ | (0.16 | ) | ||||
| Weighted average number of common shares – diluted | 48,143,819 | 46,063,803 | 47,613,577 | 41,995,266 | ||||||||||||
STREAMLINE HEALTH SOLUTIONS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(rounded to the nearest thousand dollars, except share and per share information)
| October 31, 2022 (unaudited) | January 31, 2022 | |||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 11,699,000 | $ | 9,885,000 | ||||
| Accounts receivable, net | 3,322,000 | 3,823,000 | ||||||
| Contract receivables | 831,000 | 843,000 | ||||||
| Prepaid and other current assets | 946,000 | 568,000 | ||||||
| Total current assets | 16,798,000 | 15,119,000 | ||||||
| Non-current assets: | ||||||||
| Property and equipment, net | 93,000 | 123,000 | ||||||
| Right of use asset for operating lease | 80,000 | 218,000 | ||||||
| Capitalized software development costs, net | 5,697,000 | 5,555,000 | ||||||
| Intangible assets, net | 15,244,000 | 16,763,000 | ||||||
| Goodwill | 23,089,000 | 23,089,000 | ||||||
| Other | 1,216,000 | 948,000 | ||||||
| Total non-current assets | 45,419,000 | 46,696,000 | ||||||
| Total assets | $ | 62,217,000 | $ | 61,815,000 | ||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 405,000 | $ | 778,000 | ||||
| Accrued expenses | 3,289,000 | 1,803,000 | ||||||
| Current portion of term loan | 625,000 | 250,000 | ||||||
| Deferred revenues | 5,531,000 | 5,794,000 | ||||||
| Current portion of lease obligation | 87,000 | 204,000 | ||||||
| Acquisition earnout liability | 8,645,000 | 4,672,000 | ||||||
| Total current liabilities | 18,582,000 | 13,501,000 | ||||||
| Non-current liabilities: | ||||||||
| Term loan, net of current portion and deferred financing costs | 9,214,000 | 9,654,000 | ||||||
| Deferred revenues, less current portion | 148,000 | 136,000 | ||||||
| Lease obligations, less current portion | — | 33,000 | ||||||
| Acquisition earnout liability, less current portion | — | 4,161,000 | ||||||
| Other non-current liabilities | 109,000 | 286,000 | ||||||
| Total non-current liabilities | 9,471,000 | 14,270,000 | ||||||
| Total liabilities | 28,053,000 | 27,771,000 | ||||||
| Stockholders’ equity: | ||||||||
| Common Stock, $0,.01 par value, 85,000,000 shares authorized; 55,130,334 and 47,840,950 shares issued and outstanding, respectively | 551,000 | 478,000 | ||||||
| Additional paid in capital | 128,469,000 | 119,225,000 | ||||||
| Accumulated deficit | (94,856,000 | ) | (85,659,000 | ) | ||||
| Total stockholders’ equity | 34,164,000 | 34,044,000 | ||||||
| Total liabilities and stockholders’ equity | $ | 62,217,000 | $ | 61,815,000 | ||||
STREAMLINE HEALTH SOLUTIONS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(rounded to the nearest thousand dollars)
| Nine months Ended October 31, | ||||||||
| 2022 | 2021 | |||||||
| Net Loss | $ | (9,197,000 | ) | $ | (6,512,000 | ) | ||
| LESS: Income from discontinued operations, net of tax | — | 401,000 | ||||||
| Loss from continuing operations, net of tax | (9,197,000 | ) | (6,913,000 | ) | ||||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation | 40,000 | 53,000 | ||||||
| Amortization of capitalized software development costs | 1,293,000 | 1,430,000 | ||||||
| Amortization of intangible assets | 1,519,000 | 721,000 | ||||||
| Amortization of other deferred costs | 360,000 | 369,000 | ||||||
| Change in fair value of acquisition earnout liability | (188,000 | ) | 417,000 | |||||
| Loss on early extinguishment of debt | — | 43,000 | ||||||
| Amortization of deferred financing costs | 60,000 | — | ||||||
| Share-based compensation expense | 1,212,000 | 1,659,000 | ||||||
| Provision for accounts receivable allowance | 21,000 | 14,000 | ||||||
| Forgiveness of PPP loan and accrued interest | — | (2,327,000 | ) | |||||
| Changes in assets and liabilities: | ||||||||
| Accounts and contract receivables | 492,000 | 666,000 | ||||||
| Other assets | (868,000 | ) | (551,000 | ) | ||||
| Accounts payable | (373,000 | ) | (72,000 | ) | ||||
| Accrued expenses and other liabilities | 1,159,000 | 774,000 | ||||||
| Deferred revenue | (251,000 | ) | (305,000 | ) | ||||
| Net cash used in operating activities | (4,721,000 | ) | (4,022,000 | ) | ||||
| Net cash provided by operating activities – discontinued operations | — | 406,000 | ||||||
| Cash flows from investing activities: | ||||||||
| Investment in Avelead, Net of Cash | — | (12,354,000 | ) | |||||
| Proceeds from sale of ECM Assets | — | 800,000 | ||||||
| Purchases of property and equipment | (10,000 | ) | (18,000 | ) | ||||
| Capitalization of software development costs | (1,435,000 | ) | (1,048,000 | ) | ||||
| Net cash (used in) provided by investing activities | (1,445,000 | ) | (12,620,000 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Repayment of bank term loan | (125,000 | ) | — | |||||
| Proceeds from issuance of term loan | — | 10,000,000 | ||||||
| Proceeds from issuance of common stock | 8,316,000 | 16,100,000 | ||||||
| Payments for costs directly attributable to the issuance of common stock | (52,000 | ) | (1,313,000 | ) | ||||
| Payments related to settlement of employee share-based awards | (165,000 | ) | (380,000 | ) | ||||
| Payment for deferred financing costs | — | (168,000 | ) | |||||
| Other | 6,000 | (3,000 | ) | |||||
| Net cash provided by financing activities | 7,980,000 | 24,236,000 | ||||||
| Net increase in cash and cash equivalents | 1,814,000 | 8,000,000 | ||||||
| Cash and cash equivalents at beginning of period | 9,885,000 | 2,409,000 | ||||||
| Cash and cash equivalents at end of period | $ | 11,699,000 | $ | 10,409,000 | ||||
STREAMLINE HEALTH SOLUTIONS, INC.
NEW BOOKINGS
(rounded to the nearest thousand dollars)
| October 31, 2022 | ||||||||
| Three Months Ended | Nine Months Ended | |||||||
| Software Licenses | $ | — | $ | 52,000 | ||||
| Professional Services | 123,000 | 1,538,000 | ||||||
| Audit Services | 81,000 | 118,000 | ||||||
| Maintenance and Support | 17,000 | 56,000 | ||||||
| Software as a Service | 1,650,000 | 14,122,000 | ||||||
| Q3 2022 Bookings | $ | 1,871,000 | $ | 15,886,000 | ||||
| Q3 2021 Bookings* | $ | 2,089,000 | $ | 6,296,000 | ||||
*Bookings are presented on a total contract value basis, and include Avelead from the acquisition date, August 16, 2021
STREAMLINE HEALTH SOLUTIONS, INC.
RECONCILIATION OF LOSS FROM CONTINUING OPERATIONS TO NON-GAAP ADJUSTED EBITDA
(in thousands except share amounts, unaudited)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| In thousands, except per share data | October 31, 2022 | October 31, 2021 | October 31, 2022 | October 31, 2021 | ||||||||||||
| Adjusted EBITDA Reconciliation | ||||||||||||||||
| Loss from continuing operations | $ | (3,138 | ) | $ | (4,379 | ) | $ | (9,197 | ) | $ | (6,913 | ) | ||||
| Interest expense | 198 | 85 | 519 | 107 | ||||||||||||
| Income tax expense | 9 | 4 | 22 | 9 | ||||||||||||
| Depreciation | 13 | 16 | 40 | 53 | ||||||||||||
| Amortization of capitalized software development costs | 446 | 446 | 1,293 | 1,430 | ||||||||||||
| Amortization of intangible assets | 463 | 490 | 1,519 | 721 | ||||||||||||
| Amortization of other costs | 131 | 110 | 360 | 338 | ||||||||||||
| EBITDA | $ | (1,878 | ) | $ | (3,228 | ) | $ | (5,444 | ) | $ | (4,255 | ) | ||||
| Share-based compensation expense | 555 | 537 | 1,212 | 1,659 | ||||||||||||
| Non-cash valuation adjustments | (163 | ) | 417 | (188 | ) | 417 | ||||||||||
| Acquisition-related costs, severance, and transaction-related bonuses | 387 | 1,953 | 1,010 | 2,730 | ||||||||||||
| Forgiveness of PPP loan and accrued interest | — | — | — | (2,327 | ) | |||||||||||
| Other non-recurring charges | (73 | ) | — | (140 | ) | 16 | ||||||||||
| Loss on early extinguishment of debt | — | 43 | — | 43 | ||||||||||||
| Adjusted EBITDA | $ | (1,172 | ) | $ | (278 | ) | $ | (3,550 | ) | $ | (1,717 | ) | ||||
| Adjusted EBITDA per Diluted Share Reconciliation | ||||||||||||||||
| Loss from continuing operations per common share — diluted | $ | (0.07 | ) | $ | (0.10 | ) | $ | (0.19 | ) | $ | (0.17 | ) | ||||
| Net loss per common share — diluted (2) | $ | (0.07 | ) | $ | (0.10 | ) | $ | (0.19 | ) | $ | (0.16 | ) | ||||
| Adjusted EBITDA per adjusted diluted share (1) | $ | (0.02 | ) | $ | (0.01 | ) | $ | (0.08 | ) | $ | (0.04 | ) | ||||
| Basic weighted average shares | 47,730,009 | 45,709,952 | 47,329,923 | 41,498,873 | ||||||||||||
| Includable incremental shares — adjusted EBITDA (3) | 413,810 | 353,851 | 283,654 | 496,393 | ||||||||||||
| Adjusted diluted shares | 48,143,819 | 46,063,803 | 47,613,577 | 41,995,266 | ||||||||||||
| (1) | Adjusted EBITDA per adjusted diluted share for the Company’s common stock is computed using the treasury stock method. Since the Company was in a loss position for the periods presented, adjusted EBITDA per adjusted diluted share is the same as adjusted EBITDA per adjusted share as the inclusion of all potential common shares outstanding would have been anti-dilutive. |
| (2) | Since the Company was in a loss position for the periods presented, diluted net loss per common share is the same as basic net loss per common share as the inclusion of all potential common shares outstanding would have been anti-dilutive. |
| (3) | The number of incremental shares that would be dilutive under an assumption that the Company is profitable during the reported period, which is only applicable for a period in which the Company reports profit. |
| Last Trade: | US$2.98 |
| Daily Change: | -0.42 -12.35 |
| Daily Volume: | 32,177 |
| Market Cap: | US$188.690M |
October 08, 2024 July 16, 2024 July 02, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
